series-a
Stage
2
Investors
About
Mironid develops novel small-molecule therapeutics targeting cAMP degrading phosphodiesterase enzymes to treat Autosomal Dominant Polycystic Kidney Disease (ADPKD) and other rare kidney diseases with high unmet medical needs.
Explore Mironid's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.